Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02609776 · ClinicalTrials.gov registry record · Phase 1

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
751
Enrollment target
20
Study locations

NCT02609776 is a Phase 1 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 751 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02609776, a Phase 1 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
751 participants
Enrollment target
20
Study locations

Study Summary

The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG Amivantamab
  • DRUG Lazertinib

Study Locations (20)

California

  • - Duarte
  • - La Jolla
  • - Orange
  • - Santa Monica
  • - West Hollywood

Other

  • - Camperdown
  • - Heidelberg
  • - Kogarah

Florida

  • - Tampa

Illinois

  • - Chicago

Maryland

  • - Bethesda

Massachusetts

  • - Boston

Michigan

  • - Detroit

Minnesota

  • - Rochester

Trial Details

FieldValue
Enrollment Target 751 participants
Start Date 2016-05-24
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02609776

The ClinicalTrials.gov registry entry for NCT02609776 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT02609776 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT02609776 about?

NCT02609776 is a clinical study titled "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer". The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and t...

What is the current status of trial NCT02609776?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 751 participants. The study started on 2016-05-24. Estimated completion is 2026-12-31.

What conditions does trial NCT02609776 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT02609776?

The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Amivantamab (DRUG), Lazertinib (DRUG).

Who is sponsoring clinical trial NCT02609776?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02609776 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.